Literature DB >> 28360552

Clinical, Neurocognitive, Structural Imaging and Dermatogliphics in Schizophrenia According to Kraepelin Criteria.

Hüseyin Güleç1, Semra Ulusoy Kaymak2, Mustafa Bilici1, Ali Gangal3, Temel Kayikç Ioğlu3, Ahmet Sari4, Üner Tan5.   

Abstract

INTRODUCTION: A century ago, Kraepelin stated that the distinctive feature of schizophrenia was progressive deterioration. Kraepelin criteria for schizophrenia are: (1) continuous hospitalization or complete dependence on others for obtaining basic necessities of life, (2) unemployment and (3) no remission for the past five years. We aimed to determine the clinical appearance and structural biological features of Kraepelinian schizophrenia.
METHODS: The sample consisted of 17 Kraepelinian patients, 30 non-Kraepelinian schizophrenic patients and 43 healthy controls. The Clinical Global Impressions (CGI) and the Positive and Negative Syndrome Scales (PANSS) were used for clinical assessment. The Frontal Assessment Battery (FAB) and the Verbal Fluency and Color Trail Test (CTT) were included in the cognitive battery. Brain magnetic resonance imaging and dermatoglyphic measurements were performed for structural features. RESULT: Duration of illness, hospitalization, suicide attempts, admission type, presence of a stressor and treatment choice were similar between the two patient groups. Treatment resistance and family history of schizophrenia were more common in Kraepelinian patients. PANSS and CGI subscales scores were also higher in this group. Only the category fluency and CTT-I were different in Kraepelinian patients in comparison to the other patient group. Structural findings were not different between the three groups.
CONCLUSION: Category fluency, which was lower in Kraepelinian patients, is an important marker of a degenerative process. The collection of severe clinical symptoms, family history of psychiatric illness and nonresponse to treatment in this particular group of patients points to the need to conduct further studies including cluster analysis in methodology.

Entities:  

Keywords:  Kraepelin; cognitive functions; dermatogliphic; magnetic resonance imaging; schizophrenia

Year:  2013        PMID: 28360552      PMCID: PMC5363444          DOI: 10.4274/npa.y6504

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  28 in total

1.  Differentiating between low and high susceptibility to schizophrenia in twins: the significance of dermatoglyphic indices in relation to other determinants of brain development.

Authors:  C J van Oel; W F Baaré; H E Hulshoff Pol; J Haag; J Balazs; A Dingemans; R S Kahn; M M Sitskoorn
Journal:  Schizophr Res       Date:  2001-12-01       Impact factor: 4.939

2.  Is reduced dermatoglyphic a-b ridge count a reliable marker of developmental impairment in schizophrenia?

Authors:  P Fearon; A Lane; M Airie; J Scannell; A McGowan; M Byrne; M Cannon; D Cotter; P Murphy; B Cassidy; J Waddington; C Larkin; E O'Callaghan
Journal:  Schizophr Res       Date:  2001-07-01       Impact factor: 4.939

3.  Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.

Authors:  Ridha Joober; Guy A Rouleau; Samarthji Lal; David Bloom; Pierre Lalonde; Alain Labelle; Chawki Benkelfat
Journal:  Schizophr Res       Date:  2005-09-01       Impact factor: 4.939

4.  Correlations between MRI-assessed volumes of the thalamus and cortical Brodmann's areas in schizophrenia.

Authors:  Serge A Mitelman; Adam M Brickman; Lina Shihabuddin; Randall Newmark; King Wai Chu; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2004-12-08       Impact factor: 4.939

5.  Clinical characteristics and risk factors for Kraepelinian subtype of schizophrenia: replication of previous findings and relation to summer birth.

Authors:  Marie-Cécile Bralet; Gwenolé Loas; Valerie Yon; V Maréchal
Journal:  Psychiatry Res       Date:  2002-08-30       Impact factor: 3.222

6.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

7.  Neuropsychological impairment in first-episode and chronic schizophrenic patients.

Authors:  M Albus; W Hubmann; C Ehrenberg; U Forcht; F Mohr; N Sobizack; C Wahlheim; S Hecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

8.  Neurological abnormalities in schizophrenic patients and their siblings.

Authors:  B Ismail; E Cantor-Graae; T F McNeil
Journal:  Am J Psychiatry       Date:  1998-01       Impact factor: 18.112

9.  Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: a diffusion tensor imaging survey.

Authors:  Serge A Mitelman; Yuliya Torosjan; Randall E Newmark; Jason S Schneiderman; King-Wai Chu; Adam M Brickman; M Mehmet Haznedar; Erin A Hazlett; Cheuk Y Tang; Lina Shihabuddin; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2007-02-27       Impact factor: 4.939

10.  Dermatoglyphics in patients with schizophrenia.

Authors:  Fereshteh Shakibaei; Ghorban Ali Asadollahi; Amirpooyan Tabibi
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

View more
  1 in total

1.  What is the optimal neuropsychological test battery for schizophrenia in China?

Authors:  Chuan Shi; Lan Kang; Shuqiao Yao; Yibin Ma; Tao Li; Ying Liang; Zhang Cheng; Yifeng Xu; Jianguo Shi; Xiufeng Xu; Congpei Zhang; Donald R Franklin; Robert K Heaton; Hua Jin; Xin Yu
Journal:  Schizophr Res       Date:  2019-02-01       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.